Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2023 | Updated Phase I study results of PHE885 in patients with R/R multiple myeloma

Nikhil Munshi • 9 Jun 2023
ASCO 2023
Multiple Myeloma CAR-T PHE885

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the features and advantages of PHE885, a CAR-T therapy manufactured in less than two days, which allows the product to preserve T-cell stemness. The Phase I study (NCT04318327) reported an overall response rate (ORR) of 98%.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nikhil Munshi

The interaction between bone marrow stromal cells and tumor cells as a potential target in WM 1:32
The interaction between bone marrow stromal cells and tumor cells as a potential target in WM
Nikhil Munshi • 19 Oct 2024
Immunotherapies in the future treatment landscape for Waldenström’s macroglobulinemia 1:04
Immunotherapies in the future treatment landscape for Waldenström’s macroglobulinemia
Nikhil Munshi • 19 Oct 2024
The potential of early intervention for high-risk patients with Waldenström’s macroglobulinemia 0:47
The potential of early intervention for high-risk patients with Waldenström’s macroglobulinemia
Nikhil Munshi • 19 Oct 2024
Long noncoding RNAs represent potential therapeutic targets in multiple myeloma 1:56
Long noncoding RNAs represent potential therapeutic targets in multiple myeloma
Nikhil Munshi • 11 Dec 2023

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals